IBR2, a novel small molecule that inhibits cancer cell growth and induces apoptosis by inducing proteasome-mediated RAD51 protein degradation, significantly prolonged animal survival in a murine imatinib-resistant CML model bearing the T315I Bcr-Abl mutation. The gene discussed is RAD51; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.